EN DE
STOCK COMPARISON

Compucom Software vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Compucom Software (COMPUSOFT) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Compucom Software trades at ₹13.28 versus a fair value of ₹6.18 (-53%), while Fredun Pharmaceuticals trades at ₹1,394 versus ₹2,019 (+45%).
Compucom Software
COMPUSOFT.NSE · INR · Consumer Discretionary
-53%
upside to fair value
overvalued
Price₹13.28
Fair Value₹6.18
Quality50/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+45%
upside to fair value
undervalued
Price₹1,394
Fair Value₹2,019
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Compucom SoftwareFredun Pharmaceuticals
Valuation
36.9×P/E (TTM)42.2×
3.08×P/S (TTM)2.23×
0.74×P/B5.03×
33.7×EV/EBITDA15.5×
1.9%Dividend yield0.0%
₹0.25Dividend per share₹0.70
Profitability
8%Net margin5%
-51%Operating margin12%
2%Return on equity16%
-1%Return on assets9%
Growth
-17%Revenue growth (YoY)27%
-14.5%Avg. growth/yr (3Y)32.2%
14.6%Avg. growth/yr (5Y)36.9%
Balance & size
0.15×Debt / equity0.20×
$11MMarket cap$149M
expensiveGrowth qualityexpensive

Fredun Pharmaceuticals leads: 5 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Compucom Softwareof which business quality 51 · market factors 34 Fredun Pharmaceuticalsof which business quality 35 · market factors 52
ProfitabilityMargins and returns on capital today
18
48
Quality GrowthAre margins and returns improving?
25
73
CashflowEarnings quality: real cash, not paper profit
50
5
Fin. StrengthBalance sheet, leverage, solvency risk
75
57
InvestmentDisciplined investing over empire-building
56
16
Low VolatilityCalm price path (market factor)
76
43
MomentumPrice trend over the last 3–12 months (market factor)
22
50
52W MomentumDistance to the 52-week high (market factor)
6
64
Net IssuanceBuybacks instead of dilution
90
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Compucom Software

Earnings-Based₹3.71
Dividend Discount₹2.34
Multiples₹6.21
Asset-Based₹12.04
Economic Profit₹11.20
Growth Earnings₹6.50

11 of 11 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Compucom Software
Bear ₹4.64Fair Value ₹6.18Bull ₹7.73
₹13.28 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,379Fair Value ₹2,019Bull ₹2,712
₹1,394 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Compucom Software · Consumer Discretionary

Quality score50 · below median
Fair value upside-53% · bottom 25%

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+45% · Top 25%

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Compucom Software trades at ₹13.28 versus a fair value of ₹6.18 (-53%), while Fredun Pharmaceuticals trades at ₹1,394 versus ₹2,019 (+45%).

Compucom Software has the higher quality score (50/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.